MIRA Pharmaceuticals (MIRA), a preclinical-stage pharmaceutical company, has announced promising results from safety studies on Ketamir-2, a novel oral ketamine analog. The findings, which reveal no safety concerns, mark a major milestone as the company prepares for Phase 1 human trials in early 2025. “Advancing Ketamir-2 into clinical trials reflects our dedication to creating a […]